Navigation Links
Terumo Cardiovascular Systems Files Patent Infringement Complaint Against Maquet Affiliates
Date:7/9/2008

ANN ARBOR, Mich., July 9 /PRNewswire/ -- Terumo Cardiovascular Systems (Terumo CVS) announced that it has filed a patent infringement complaint in Germany against two affiliates of Maquet Cardiovascular LLC: Maquet GmbH & Co. KG and Maquet Vertriebs und Service Deutschland GmbH. The complaint alleges that two Maquet products, Vasoview(R) 6 and Vasoview(R) 7 Endoscopic Vessel Harvesting Systems, infringe a patent for which Terumo CVS owns the rights in Germany. The complaint also requests an injunction against further sales of the product there.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061027/DEF004LOGO )

Terumo CVS sells the VirtuoSaph(TM) Endoscopic Vessel Harvesting System in the United States. The VirtuoSaph system is distributed in Japan and Asia by Terumo Corporation and in Europe by Terumo's European subsidiary.

"Terumo respects the valid intellectual property of others and expects that its competitors will do the same," said Mark Sutter, President and CEO, Terumo Cardiovascular Systems.

The VirtuoSaph system is used during coronary artery bypass grafting (CABG), the most common cardiac surgery procedure. During the procedure, the surgeon removes a healthy artery or vein from elsewhere in the body, most often the saphenous vein in the leg, and uses it to route blood around a blockage in a coronary artery. The VirtuoSaph system allows the surgical team to remove the saphenous vein using very small incisions. Endoscopic procedures have been shown to minimize scarring, morbidity and infection associated with traditional longitudinal incisions.

Terumo Cardiovascular Systems Corporation is a global manufacturer and marketer of medical devices for cardiac and vascular surgery. The company is headquartered in Ann Arbor, Michigan with manufacturing operations in Ann Arbor; Elkton, Maryland; Ashland, Massachusetts; and Tustin, California. It is one of several subsidiaries of Terumo Corporation of Japan focused exclusively on the cardiac and vascular markets, including Terumo Heart Inc., developer of a ventricular assist device, and Vascutek, Ltd, leading manufacturer of vascular grafts. For more information, visit http://www.terumo-cvs.com .

Terumo Corporation is a premier global medical device company with annual sales of nearly three billion dollars for the year ending March 31, 2008. Founded in 1921, the company develops, manufactures and distributes world-class medical devices for use in cardiothoracic surgery, interventional procedures, transfusion medicine, and needle and syringe products.


'/>"/>
SOURCE Terumo Cardiovascular Systems
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
2. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
3. NFL Hall of Fame Legend Fred Biletnikoff Joins AFL/Signalife Cardiovascular Protection Team
4. Amarin Announces Initiation of Cardiovascular Development Strategy
5. VIA Pharmaceuticals Lead Compound, VIA-2291, Chosen as a Top Ten Most Licensable Cardiovascular Program for Windhover Informations Therapeutic Area Partnerships Conference
6. VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
7. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
8. HealthAware Introduces Its VascularAware Cardiovascular Disease Module
9. Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over
10. BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
11. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , ... May 26, 2016 , ... ... company, today announced several positive developments that position the Company for the future. ... of the transaction, Craig F. Kinghorn has been appointed Chairman of the Board, ...
(Date:5/25/2016)... ... May 25, 2016 , ... Founder of the Fitzmaurice ... surgery and surgery of the hand by the National Board of Physicians and ... above and beyond in his pursuit of providing the most comprehensive, effective treatment ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... ... U.S. Food and Drug Administration (FDA) has granted the company’s orphan drug designation ... company’s second orphan drug designation granted by the FDA. , Spinocerebellar ataxia ...
(Date:5/23/2016)... , ... May 23, 2016 , ... The need for blood donations in South Texas ... by the South Texas Blood & Tissue Center, blood donations are on the decline. In ... and they are down 21 percent in South Texas in the last four years alone. ...
Breaking Biology Technology:
(Date:3/15/2016)... New York , March 15, 2016 ... new market report published by Transparency Market Research "Digital Door ... Trends and Forecast 2015 - 2023," the global digital door ... US$ 731.9 Mn in 2014 and is forecast to grow ... 2023. Growth of micro, small and medium enterprises (MSMEs) across ...
(Date:3/14/2016)... -- NXTD ) ("NXT-ID" or the "Company"), a ... airing of a new series of commercials on Time Warner ... st .  The commercials will air on Bloomberg TV, Fox ... Street show. --> NXTD ) ("NXT-ID" or the ... announces the airing of a new series of commercials on ...
(Date:3/11/2016)... HANOVER, Germany , March 11, 2016 ... - Cross reference: Picture is available at AP Images ( ... scanner from DERMALOG will be used to produce the new refugee ... of other biometric innovations, at CeBIT in Hanover ... LF10 scanner from DERMALOG will be used to produce the new ...
Breaking Biology News(10 mins):